Russell Investments Group Ltd. Acquires 16,720 Shares of Artivion, Inc. (NYSE:AORT)

Russell Investments Group Ltd. grew its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,360 shares of the company's stock after buying an additional 16,720 shares during the period. Russell Investments Group Ltd. owned 0.34% of Artivion worth $4,127,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Artivion by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company's stock worth $10,241,000 after purchasing an additional 8,343 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Artivion in the 3rd quarter worth $5,798,000. Principal Financial Group Inc. raised its holdings in Artivion by 3.8% during the fourth quarter. Principal Financial Group Inc. now owns 202,028 shares of the company's stock valued at $5,776,000 after acquiring an additional 7,398 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Artivion by 64.2% in the fourth quarter. JPMorgan Chase & Co. now owns 160,796 shares of the company's stock worth $4,597,000 after acquiring an additional 62,893 shares during the period. Finally, Tidal Investments LLC grew its position in shares of Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company's stock worth $4,179,000 after purchasing an additional 134,642 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors.

Artivion Price Performance

Artivion stock traded down $0.33 during mid-day trading on Monday, reaching $22.60. 371,378 shares of the company's stock traded hands, compared to its average volume of 295,708. Artivion, Inc. has a 12-month low of $19.36 and a 12-month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average of $24.90 and a two-hundred day moving average of $27.35. The company has a market cap of $964.77 million, a price-to-earnings ratio of -1,130.00 and a beta of 1.65.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to analysts' expectations of $100.82 million. Equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Transactions at Artivion

In related news, insider John E. Davis sold 15,100 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the sale, the insider now directly owns 208,778 shares of the company's stock, valued at $4,929,248.58. This represents a 6.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 18,020 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the transaction, the senior vice president now owns 197,184 shares of the company's stock, valued at $4,655,514.24. This trade represents a 8.37 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AORT shares. Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Needham & Company LLC reduced their price target on shares of Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion currently has a consensus rating of "Buy" and a consensus price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.